Coronado Biosciences, Inc. to Present at the 2012 JMP Securities Healthcare Conference
July 03, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., July 3, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences, Inc. Announces Closing of $28.8 Million Public Offering
June 27, 2012 17:12 ET
|
Coronado Biosciences
BURLINGTON, Mass., June 27, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences Added to Russell 3000(R) Index
June 25, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., June 25, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment...
Coronado Biosciences, Inc. Announces the Pricing of Public Offering of Common Stock
June 22, 2012 07:50 ET
|
Coronado Biosciences
BURLINGTON, Mass., June 22, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences Receives Orphan-Drug Designation From FDA for CNDO-109-Activated Allogeneic Natural Killer Cells for the Treatment of AML
June 19, 2012 10:34 ET
|
Coronado Biosciences
BURLINGTON, Mass., June 19, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences Receives Notice of Allowance for First U.S. Patent Covering CNDO-109
June 08, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., June 8, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences, Inc. Files Registration Statement for Proposed Public Offering
June 04, 2012 07:08 ET
|
Coronado Biosciences
BURLINGTON, Mass., June 4, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the...
Coronado Biosciences Reports Financial Results for the First Quarter Ended March 31, 2012
May 15, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., May 15, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences to Report First Quarter 2012 Financial Results
May 10, 2012 08:30 ET
|
Coronado Biosciences
BURLINGTON, Mass., May 10, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...
Coronado Biosciences Announces Phase 1 TSO Data to be Presented at the 8th International Congress on Autoimmunity
May 01, 2012 07:00 ET
|
Coronado Biosciences
BURLINGTON, Mass., May 1, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of...